Cargando…

Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2

Crystalline deposits and neurosensory retinal cavitary changes can develop in both tamoxifen retinopathy and nonproliferative idiopathic macular telangiectasia type 2 (MacTel2). MacTel2 is typically differentiated from tamoxifen retinopathy based on the presence of late leakage and mid-phase telangi...

Descripción completa

Detalles Bibliográficos
Autores principales: Behrens, Alice, Sallam, Ahmed, Pemberton, John, Uwaydat, Sami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892311/
https://www.ncbi.nlm.nih.gov/pubmed/29643783
http://dx.doi.org/10.1159/000485739
_version_ 1783313151796707328
author Behrens, Alice
Sallam, Ahmed
Pemberton, John
Uwaydat, Sami
author_facet Behrens, Alice
Sallam, Ahmed
Pemberton, John
Uwaydat, Sami
author_sort Behrens, Alice
collection PubMed
description Crystalline deposits and neurosensory retinal cavitary changes can develop in both tamoxifen retinopathy and nonproliferative idiopathic macular telangiectasia type 2 (MacTel2). MacTel2 is typically differentiated from tamoxifen retinopathy based on the presence of late leakage and mid-phase telangiectatic vessels on fluorescein angiography (FA) and the presence of hyperautofluorescence. Unlike MacTel2, tamoxifen retinopathy is known to be a progressive disease and the cessation of tamoxifen results in resolution of retinopathy. We report a unique case of nonproliferative MacTel2 in a 36-year-old Hispanic woman with tamoxifen use and the vision outcome 30 months after cessation of tamoxifen. The FA and optical coherence tomography angiography findings of this patient support the diagnosis of MacTel2, but her cessation of tamoxifen led to partial reversal of the topographic findings and improvement in visual acuity. This patient is also unique in the unusually young age of presentation for MacTel2. Our case supports that there are common pathways in the pathogenesis of tamoxifen retinopathy and MacTel2, and tamoxifen use could potentially accelerate foveal atrophy in patients with MacTel2.
format Online
Article
Text
id pubmed-5892311
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-58923112018-04-11 Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2 Behrens, Alice Sallam, Ahmed Pemberton, John Uwaydat, Sami Case Rep Ophthalmol Case Report Crystalline deposits and neurosensory retinal cavitary changes can develop in both tamoxifen retinopathy and nonproliferative idiopathic macular telangiectasia type 2 (MacTel2). MacTel2 is typically differentiated from tamoxifen retinopathy based on the presence of late leakage and mid-phase telangiectatic vessels on fluorescein angiography (FA) and the presence of hyperautofluorescence. Unlike MacTel2, tamoxifen retinopathy is known to be a progressive disease and the cessation of tamoxifen results in resolution of retinopathy. We report a unique case of nonproliferative MacTel2 in a 36-year-old Hispanic woman with tamoxifen use and the vision outcome 30 months after cessation of tamoxifen. The FA and optical coherence tomography angiography findings of this patient support the diagnosis of MacTel2, but her cessation of tamoxifen led to partial reversal of the topographic findings and improvement in visual acuity. This patient is also unique in the unusually young age of presentation for MacTel2. Our case supports that there are common pathways in the pathogenesis of tamoxifen retinopathy and MacTel2, and tamoxifen use could potentially accelerate foveal atrophy in patients with MacTel2. S. Karger AG 2018-01-17 /pmc/articles/PMC5892311/ /pubmed/29643783 http://dx.doi.org/10.1159/000485739 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Behrens, Alice
Sallam, Ahmed
Pemberton, John
Uwaydat, Sami
Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2
title Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2
title_full Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2
title_fullStr Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2
title_full_unstemmed Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2
title_short Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2
title_sort tamoxifen use in a patient with idiopathic macular telangiectasia type 2
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892311/
https://www.ncbi.nlm.nih.gov/pubmed/29643783
http://dx.doi.org/10.1159/000485739
work_keys_str_mv AT behrensalice tamoxifenuseinapatientwithidiopathicmaculartelangiectasiatype2
AT sallamahmed tamoxifenuseinapatientwithidiopathicmaculartelangiectasiatype2
AT pembertonjohn tamoxifenuseinapatientwithidiopathicmaculartelangiectasiatype2
AT uwaydatsami tamoxifenuseinapatientwithidiopathicmaculartelangiectasiatype2